Tumor lysis syndrome in children with hematological malignancies: a nephrology perspective in resource-limited settings.
1/5 보강
[BACKGROUND] Tumor lysis syndrome (TLS) is a major metabolic emergency in pediatric oncology and a leading cause of acute kidney injury (AKI) in children with hematological malignancies.
APA
Elshafey SA, Essa L, et al. (2026). Tumor lysis syndrome in children with hematological malignancies: a nephrology perspective in resource-limited settings.. Frontiers in oncology, 16, 1778776. https://doi.org/10.3389/fonc.2026.1778776
MLA
Elshafey SA, et al.. "Tumor lysis syndrome in children with hematological malignancies: a nephrology perspective in resource-limited settings.." Frontiers in oncology, vol. 16, 2026, pp. 1778776.
PMID
41883964 ↗
Abstract 한글 요약
[BACKGROUND] Tumor lysis syndrome (TLS) is a major metabolic emergency in pediatric oncology and a leading cause of acute kidney injury (AKI) in children with hematological malignancies. Early identification of children at risk for severe AKI remains challenging.
[METHODS] This retrospective study included 50 children with laboratory or clinical TLS diagnosed according to the Howard-Pui classification. Serial biochemical parameters were analyzed over a 10-day period. AKI severity was classified using the pediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria based on changes in estimated glomerular filtration rate (eGFR). Clinical characteristics, biochemical trends (especially phosphate and uric acid), and outcomes were compared between children with mild (pRIFLE 0 [no AKI]/R/I) and severe (pRIFLE-F) AKI.
[RESULTS] Twenty-seven patients had acute lymphoblastic leukemia (ALL), and 23 had lymphoma, mainly Burkitt's lymphoma. Clinical TLS accounted for 86% of cases, and 60% of children developed severe AKI. Severe AKI was significantly associated with spontaneous TLS onset, prolonged TLS duration, increased need for kidney therapy, intensive care admission, and higher mortality. Static demographic characteristics, malignancy type, tumor burden, and radiological findings did not differ between AKI severity groups. While hyperphosphatemia and hyperuricemia were common, dynamic phosphate changes showed the strongest association with AKI severity. The daily rise in serum phosphate before AKI onset demonstrated good discriminatory performance for predicting severe AKI (AUC 0.839), outperforming changes in uric acid.
[CONCLUSION] In pediatric TLS, AKI severity is the main determinant of clinical outcome. Dynamic phosphate kinetics (Delta phosphorus), rather than static biochemical thresholds, represent a robust early biomarker for identifying children at risk of severe AKI and may improve risk stratification, particularly in resource-limited settings.
[METHODS] This retrospective study included 50 children with laboratory or clinical TLS diagnosed according to the Howard-Pui classification. Serial biochemical parameters were analyzed over a 10-day period. AKI severity was classified using the pediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria based on changes in estimated glomerular filtration rate (eGFR). Clinical characteristics, biochemical trends (especially phosphate and uric acid), and outcomes were compared between children with mild (pRIFLE 0 [no AKI]/R/I) and severe (pRIFLE-F) AKI.
[RESULTS] Twenty-seven patients had acute lymphoblastic leukemia (ALL), and 23 had lymphoma, mainly Burkitt's lymphoma. Clinical TLS accounted for 86% of cases, and 60% of children developed severe AKI. Severe AKI was significantly associated with spontaneous TLS onset, prolonged TLS duration, increased need for kidney therapy, intensive care admission, and higher mortality. Static demographic characteristics, malignancy type, tumor burden, and radiological findings did not differ between AKI severity groups. While hyperphosphatemia and hyperuricemia were common, dynamic phosphate changes showed the strongest association with AKI severity. The daily rise in serum phosphate before AKI onset demonstrated good discriminatory performance for predicting severe AKI (AUC 0.839), outperforming changes in uric acid.
[CONCLUSION] In pediatric TLS, AKI severity is the main determinant of clinical outcome. Dynamic phosphate kinetics (Delta phosphorus), rather than static biochemical thresholds, represent a robust early biomarker for identifying children at risk of severe AKI and may improve risk stratification, particularly in resource-limited settings.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Procedural State Anxiety in Pediatric Leukemia Patients Undergoing Bone Marrow Aspiration or Lumbar Puncture: A Cross-Sectional Study Using the Chinese Version of the State Anxiety Scale for Children.
- Pediatric sequential organ failure assessment score predicts prognosis in children with acute lymphoblastic leukemia and sepsis: association with early multiple organ dysfunction.
- Impact of diagnosis-related group systems on inpatient expenditures and medical quality for children with leukemia: evidence from real-world data.
- Salvage Treatment Options for Posttransplant Relapse in Children with Early/Very Early Relapse of Acute Lymphoblastic Leukemia: A Single-Center Experience.
- Kidney Involvement in Sarcoidosis-Lymphoma Syndrome: A Report of Two Cases.
- Multicenter machine learning study for long-term prediction of acute kidney injury after complete mesocolic excision: integrating inflammatory biomarkers and transfusion-related risk factors.